Penelope Hill DennehyProfessor of Pediatrics, Vice Chair of Pediatrics
Dr Dennehy is currently Professor of Pediatrics at Brown Medical School and Director of the Division of Pediatric Infectious Diseases at Hasbro Children's Hospital in Providence, Rhode Island. She is in the practice of academic medicine and is actively involved in teaching, research and clinical care. Her primary areas of research include: the epidemiology and etiology of viral gastroenteritis and viral respiratory disease, rotavirus disease and prevention, and the testing of vaccines and immunobiologics for prevention of rotavirus, influenza and respiratory syncytial virus. She is a former member of the American Academy of Pediatrics "Redbook" Committee and Past-President of the Pediatrics Infectious Disease Society.
Kimberlin DW, Whitley RJ, Wan W, Powell DA, Storch G, Ahmed A, Palmer A, Sánchez PJ, Jacobs RF, Bradley JS, Robinson JL, Shelton M, Dennehy PH, Leach C, Rathore M, Abughali N, Wright P, Frenkel LM, Brady RC, Van Dyke R, Weiner LB, Guzman-Cottrill J, McCarthy CA, Griffin J, Jester P, Parker M, Lakeman FD, Kuo H, Lee CH, Cloud GA, National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.
Oral acyclovir suppression and neurodevelopment after neonatal herpes.
New England Journal of Medicine.
. full textPubMed
Cardo D, Dennehy PH, Halverson P, Fishman N, Kohn M, Murphy CL, Whitley RJ, HAI Elimination White Paper Writing Group, Brennan PJ, Bright J, Curry C, Graham D, Haerum B, Kainer M, Kaye K, Lundstrom T, Richards C, Tomlinson L, Skillen EL, Streed S, Young M, Septimus E.
Moving toward elimination of healthcare-associated infections: a call to action.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America.
. full textPubMed
Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefeld HR, Christie CDC, Ylitalo S, Itzler R, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM for the Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and Efficacy of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine. New England Journal of Medicine 354(1):23-33, 2006.
Dennehy PH, Brady RC, Halperin SC, Ward RL, Alvey JC, Fischer FH, Jr., Innis BL, Rathfon H, Schuind A, DeVos B, for the North American Human Rotavirus Vaccine Study Group. Comparative Evaluation of Safety and Immunogenicity of Two Dosages of an Oral Live Attenuated Human Rotavirus Vaccine. Pediatric Infectious Disease Journal 24(6):481-488, 2005.
Xu J, Dennehy P, Keyserling H, Westerman LE, Wang Y, Holman RC, Gentsch JR, Glass RI and Jiang B. Serum Antibody Responses in Children with Diarrhea Due to Rotavirus are Age Dependent and Can Serve as a Proxy for Protection. Clinical and Diagnostic Laboratory Immunology 12(2):273-279, 2005.
Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero M, Treanor J, Ward RL, Krah DL, Shaw A, Dallas MJ, Eiden JJ, Ivanoff N, Kaplan KM, and Heaton P. Safety, efficacy and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. Journal of Pediatrics, 144(2):184-90, 2004.
Jiang B, Snipes-Magaldi L, Dennehy P, Keyserling H, Holman RC, Bresee J, Gentsch J and Glass RI. Cytokines as mediators for or effectors against rotavirus disease in children. Clinical and Diagnostic Laboratory Immunology 10:995-1001, 2003.
Clark HF, Burke CJ, Volkin DB, Offit P, Ward RL, Bresee JS, Dennehy P, Gooch WM, Malacaman E, Matson D, Walter E, Watson B, Krah DL, Dallas MJ, Schödel F, Kaplan KM, and Heaton P. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatric Infectious Disease Journal 22:914-20, 2003.
Dennehy PH, Nelson SM, Spangenberger S, Noel JS, Monroe SS and Glass RI. A prospective case-control study of the role of astrovirus in acute diarrhea among hospitalized young children. Journal of Infectious Diseases. 184(1):10-5, 2001.
Begue RE, Martin P, and Dennehy PH. Serologic responses by immunoblot following natural infection with rotavirus serotypes G1 and G4 in children. J Medical Virol 56:52-57, 1998.
Dennehy PH, Rodgers GC Jr., Ward RL, Markwick AJ, Mack M, Zito ET for the US Rhesus Rotavirus Vaccine Study Group. Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. Pediatr Infect Dis J 15:1012-1018, 1996.
Jiang B, Tsunemitsu H, Dennehy PH, Oishi I, Brown D, Schnagl RD, Oseto M, Fang ZY, Avendano LF, Saif LJ and Glass RI. Sequence Conservation and expression of the gene encoding the outer capsid glycoprotein among human group C rotaviruses of global distribution. Arch Virol 141:381-390, 1996.
Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, Mack ME, Davidson BL, Kapikian AZ for the United States Rotavirus Vaccine Efficacy Group. Safety and efficacy of high dose rhesus-human reassortment rotavirus vaccines - report of the national multicenter trial. Pediatrics 97:7-13, 1996.
Jiang B, Dennehy PH, Spangenberger S, Gentsch JR, and Glass RI. First detection of group C rotavirus in fecal specimens of children with diarrhea in the United States. J Infect Dis 172:45-50, 1995.
Dennehy PH, Saracen CL and Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella (MMRV) vaccine of children with upper respiratory tract infection. Pediatrics 94:514-516, 1994.
Dennehy PH, Schutzbank TE, and Thorne GM. Evaluation of an automated immunodiagnostic assay system (VIDAS Rotavirus) for the detection of rotavirus in fecal specimens. J Clin Microbiol 32:825-827, 1994.
Begue RE, Dennehy PH, Huang J, and Martin P. Serotype variation of group A rotaviruses over nine winter epidemics in Southeastern New England. J Clinic Microbiol 30:1592-1594, 1992.
Dennehy PH, Reisinger KS, Blatter MM, and Veloudis BA. Comparison of the immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children. Pediatrics 88:604-607, 1991.
Dennehy PH, Gauntlett DR, and Spangenberger SH. Choice of reference assay for the detection of rotavirus in fecal specimens. Electron microscopy versus enzyme immunoassay. J Clin Microbiol 28:1280-1283, 1990.
Dennehy PH, Tente WE, Fisher DJ, Veloudis BA, and Peter G. Lack of impact of rapid identification of rotavirus-infected patients on nosocomial infections. Pediatric Infect Dis J 8:290-296, 1989.
Dennehy PH and Gauntlett DR. Evaluation of new enzyme immunoassay (TESTPACK Rotavirus) for the detection of rotavirus in fecal specimens. Diagn Microbiol Infect Dis 11:201-203, 1988.
Dennehy PH, Gauntlett DR and Tente WE. Comparison of nine commercial immunoassays for the detection of rotavirus in fecal specimens. J Clin Microbiol 26:1630-1634, 1988.
Dennehy PH and Peter G. Risk factors associated with nosocomial rotavirus infectious. Am J Dis Child 139:935-939, 1985.
Dennehy PH, Hartin M, Nelson SM and Reising SF. Evaluation of the ImmunoCard STAT! Rotavirus Assay for Detection of Group A Rotavirus in Fecal Specimens. Journal of Clinical Microbiology 37:1977-1979, 1999.
Primary areas of research include: the epidemiology and etiology of viral gastroenteritis and viral respiratory disease, rotavirus disease and prevention, and the testing of vaccines and immunobiologics for prevention of rotavirus, influenza, and respiratory syncytial virus.
Rotavirus disease and prevention
Dr. Dennehy has been involved in research on the epidemiology of rotavirus infections with her most recent project a CDC funded study to look at risk factors for hospitalization with rotavirus gastroenteritis. She has also been an investigator in several randomized, placebo-controlled multicenter studies to study the safety of investigational rotavirus vaccines and their ability to prevent rotavirus disease.
The epidemiology and etiology of viral gastroenteritis
Dr. Dennehy has worked in collaboration with the Viral Gastroenteritis Unit at the CDC to characterize the role that astroviruses, caliciviruses, and noroviruses play in causing acute gastroenteritis in hospitalized children.
Pediatric vaccines, including varicella, influenza, and combination vaccines
Dr. Dennehy has been involved in studies of the nasal influenza vaccine, varicella vaccine, both as a single component vaccine and combined with measles-mumps-rubella vaccine, and combination vaccines for bacterial pathogens.
Dr. Dennehy has participated in studies of monoclonal antibodies to prevent or treat respiratory syncytial virus infections in both premature infants and those with heart disease.
"Comparison of Varying Regimens of Varicella Vaccine in Healthy Adolescents and Adults". Merck Sharp and Dohme. Site Investigator, 1990-2000, $13,600.
"Safety, Immunogenicity and Efficacy Study Comparing Multiple Doses of Oral Tetravalent Rhesus Rotavirus Vaccine with Serotype 1 Reassortment Rhesus Rotavirus Vaccine". Wyeth-Ayerst. Site Investigator, 1991-1992, $124,425.
"A Safety and Immunogenicity Trial of Two Dosage Levels of Oral Rotavirus Vaccine". Wyeth-Ayerst. Site Investigator, 1991-1992, $12,000.
"Comparison of One Versus Two Injections of Oka/Merck Varicella Vaccine in Healthy Children". Merck Sharp and Dohme. Site Investigator, 1991-2000, $120,990.
"Two Injections of New Production Lots of Oka/Merck Varicella Vaccine in Healthy Adolescents and Adults". Merck Sharp and Dohme. Site Investigator, 1991-2002, $20,590.
"Clinical Trial of the VIDAS Rotavirus Assay". Vitek Systems. Principal Investigator, 1992, $15,020.
"Live Attenuated Measles, Mumps, Rubella and Chickenpox Vaccine (MMRII-V) in Healthy Children". Merck Sharp and Dohme. Principal Investigator, 1992-2000, $106,486.
"Clinical Trial Evaluation of Immunocard Rotavirus". Meridian Diagnostics. Principal Investigator, 1993, $4,000.
"Safety, Immunogenicity and Efficacy of a Live Quadrivalent Rotavirus Vaccine in Healthy Infants". Merck & Co., Inc. Site Investigator, 1993-1994. $81,000.
"A Double-Blind Placebo-Controlled Immunogenicity and Safety Trial to Determine Whether Tetravalent Rhesus Rotavirus Vaccine Interferes with DPT and Hib Vaccines in Healthy Infants". Wyeth-Ayerst Research. Site Investigator, 1994-1995, $97,434.
"A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Monthly RespiGam (RSVIG-IV) Infusions for Reduction of the Rate of RSV Hospitalization in Premature Infants and Infants with Bronchopulmonary Dysplasia". MedImmune, Inc. Site Investigator, 1994-1995, $44,514.
"A Single-Blind Comparative Trial of the Safety and Immunogenicity of a Tablet Formulation of the Tetravalent Rhesus Rotavirus Vaccine (RRV-TV-TAB) Versus the Lyophilized Formulation of the Tetravalent Rhesus Rotavirus Vaccine (RRV-TV)". Wyeth-Ayerst Research. Site Investigator, 1994-1995, $20,260.
"A Single-Blind Immunogenicity and Safety Study to Determine the Consistency of Consecutively Released Lots of the Tetravalent Rhesus Rotavirus Vaccine (Rotavax)". Wyeth-Ayerst Research. Site Investigator, 1995-1996. $104,714.
"A Phase I/II Study of the Safety, Tolerance and Pharmacokinetics of MEDI-493, a Humanized Respiratory Syncytial Virus Monoclonal Antibody Conducted in Otherwise Healthy Children Hospitalized with RSV Infection". MedImmune, Inc. Site Investigator, 1996-1997, $21,356.
"A Case-Control Study of Non-Steroidal Anti-Inflammatory Drug Use as a Risk Factor for Group A Streptococcal Necrotizing Fascitis in Children". Boston University School of Medicine and CDC, Collaborator, 1996-1998.
"A Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Fourth Dose of the Tetravalent Rhesus Rotavirus Vaccine (RRV-TV) in Children 14-24 months of Age". Wyeth Lederle Vaccines and Pediatrics, Site Investigator, 1996, $49,950.
"A Pivotal Phase III Study of MEDI-493, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, for Prophylaxis of Severe RSV Disease in Premature Infants and Infants with Bronchopulmonary Dysplasia (BPD)". MedImmune, Inc., Site Investigator, 1996-1997, $72,700.
"A Phase II Study of the Safety, Tolerance and Pharmacokinetics and Effect on Viral Load in Tracheal Aspirates of MEDI-493, a Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Children on Mechanical Ventilation for Respiratory Syncytial Virus". MedImmune, Inc., Site Investigator, 1996-1997, $40,770.
"Clinical Trial of One-Step Rotavirus". Meridian Diagnostics, Inc., Principal Investigator, 1997, $8,480.
"A Phase III Trial of the Efficacy of Pertussis-IGIV". Orphan Drug Program of the FDA (P.I. Scott Halperin, Dalhousie University): Collaborator, 1997-1998, $22,581.
"Safety, Immunogenicity and Efficacy in Healthy Infants of G1 and G2 Human-Bovine Rotavirus Vaccine in a New Buffer/Stabilizer Liquid Formulation". Merck & Co., Inc., Site Investigator, 1997-1998, $64,831.
"Evaluation of the Immunogenicity of IM MEDI-493 in Children Who Previously Received IM MEDI-493 Prophylaxis and Children Receiving IM MEDI-493 for the First Time". MedImmune Inc., Site Investigator, 1997-1998, $84,195.
"Safety and Tolerability of Oral, Live G4 Human-Bovine Reassortant Rotavirus Vaccine in Healthy Adults and Healthy Infants". Merck & Co., Inc., Principal Investigator, 1998, $54,000.
"Dose-Response Study Comparing Varying Dosage Levels of Process Upgrade Varicella Vaccine in Concomitant Use with M-M-RII in Healthy Children", Merck Research Laboratories, Site Investigator, 1998-1999, $55,000.
"A Pilot Study of the Incidence of Helicobacter pylori in Infants with Colic", Meridian Diagnostics, Inc., Principal Investigator, 1998-1999, $3,000.
"Multicenter Randomized Double-Blind Safety and Tolerability Study with In-House Blinding Procedures Comparing High-Dose Potency Process Upgrade Varicella Vaccine with VARIVAX in Healthy Children", Merck Research Laboratories, Site Investigator, 1999, $45,000.
"Collection of Reference Specimens from Children with Acute Rotavirus Diarrhea", Centers for Disease Control, Principal Investigator, 1999-2001, $9,250; 2003, $5,000; 2004, $5,000; 2005, $5,000.
"Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir Treatment of Symptomatic Central Nervous System Congenital Cytomegalovirus Infections". NIAID Collaborative Antiviral Study Group, Site Investigator, 1999-2001.
"A Placebo-Controlled Phase III Evaluation of Suppressive Therapy with Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Limited to the Skin, Eye and Mouth". 1999-
"A Placebo-Controlled Phase III Evaluation of Suppressive Therapy with Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Involving the Central Nervous System". 1999-
"A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Infants with Enteroviral Meningitis". 1999-2001
"A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates with Enteroviral Sepsis Syndrome". 1999-2004
"Active Sentinal Hospital Surveillance for Rotavirus Gastroenteritis, Centers for Disease Control and Prevention". Principal Investigator, 1999-2000 $80,000,
"A Phase II Randomized, Controlled Study to Determine the Safety and Immunogenicity of Two Combination Vaccines Containing Meningococcal C and Pneumococcal Capsular Polysaccharide-CRM197 Conjugates with or without PRP-CRM197 (HibTITER) in Healthy Infants". Wyeth-Lederle Vaccines, Site Investigator, 1999-2001, $89,569.
"Comparison of the Safety, Tolerability and Immunogenicity of Three Consistency Lots of Frozen Measles, Mumps, Rubella and Varicella Vaccine (MMRV) in Healthy Children". Merck Research Laboratories, Site Investigator, 2000-2002, $80,064.
"A Phase II, Double-Blind, Randomized, Placebo-Controlled Study of Two Doses of SmithKline Beecham Biologicals' Live Attenuated Human Rotavirus Vaccine at Different Virus Concentrations in Healthy Infants Following a 0,2 Month Schedule and Previously Uninfected with Human Rotavirus". GlaxoSmithKline, Site Investigator, 2000-2002, $35,680.
"Safety and Efficacy of Pentavalent (G1, G2, G3, G4, and P1) Human-Bovine Reassortant Rotavirus Vaccine in Healthy Infants". Merck Research Laboratories, Site Investigator, 2001-2005, $259,299.
PROTOCOL MI-CP096: "A Pilot Study to Describe the Incidence Rate and Clinical Features of Human Metapneumovirus (hMPV) Infection of the Lower Respiratory Tract in Hospitalized Children at High Risk for Severe Disease". MedImmune, Inc., Site Investigator, 2003-2004 $30,000; 2004-2005 $40,000; 2005-2006.
PROTOCOL 272-00: "A Randomized, Two Period, Multicenter, Double-Blind Parallel-Group Study Comparing the Effects of Two Doses of Montelukast Granules Placebo in the Treatment of Respiratory Symptoms Associated with Respiratory Syncytial Virus-Induced Bronchiolitis in Children Aged 6 to 18 months". Merck Research Laboratories, Site Investigator, 2003-2004, $4,000.
PROTOCOL MI-CP104: "A Phase 1/2, Open-Label, Repeat-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody against Respiratory Syncytial Virus (RSV), in Children at Risk for Serious RSV Disease". MedImmune, Inc., Site Investigator, 2004, $7,380.
PROTOCOL MI-CP110: "A Pivotal Phase 3 Study of MEDI-524 (Numax), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children". MedImmune, Inc., Site Investigator, 2004, $10,955, 2005 $90,678., 2006
PROTOCOL MI-CP111: "A Randomized, Double-Blind Trial to Assess the Safety and Relative Efficacy of CAIV-T against Inactivated Influenza Vaccine in Children 6-59 Months of Age". MedImmune, Inc., Site Investigator, 2004-2005, $101,108.
PROTOCOL MI-CP124: "A Study to Evaluate the Safety, Tolerability, Pharmacokinectics and Immunogeniticy of MEDI-524 (Numax), a Humanized Enhanced Potency Monoclonal Antibody against Respiratory Syncytial Virus (RSV) in Children with Hemodynamically Significant Heart Disease". MedImmune, Inc., Site Investigator, 2005-2006, $20,085.
PROTOCOL Hib-MenCY-TT009/010: "A Phase III, Randomized, Multinational Study, Double-Blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCY-TT Vaccine Lots and Single-Blinded and Controlled for the Evaluation of Safety and Immunogenicity of GSK Biologicals' Haemophilus Influenzae Type b and Neisseria Meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine Combined (Hib-MenCY-TT) Compared to Monovalent Hib Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age". GlaxoSmithKline Biologicals, Site Investigator, 2006-2007, $102,000.
American Lung Association Training Fellowship in Pulmonary Diseases
Rhode Island Hospital, Division Teaching Award in PediatricsAmerican Health Magazine, The Best Doctors in America
Named in Best Doctors in America, Woodward and White
Dean's Teaching Excellence Award, Brown Medical School
Consumer's Research Council of America 's Guide to America's Top Pediatricians
American Academy of Pediatrics, Infectious Disease Section
American Pediatric Society
American Society for Microbiology
American Society for Virology
Eastern Society for Pediatric Research
European Society for Pediatric Infectious Diseases
Infectious Diseases Society of America, Fellow
International Society for Vaccines
Northeast Association for Clinical Microbiology and Infectious Disease
Pediatric Infectious Diseases Society, Fellow
Rhode Island Chapter, American Academy of Pediatrics
Society for Pediatric Research